318 related articles for article (PubMed ID: 32718143)
21. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; Del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; du Bois A
Gynecol Oncol; 2016 Mar; 140(3):443-9. PubMed ID: 26740259
[TBL] [Abstract][Full Text] [Related]
22. Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.
Stasenko M; Cybulska P; Feit N; Makker V; Konner J; O'Cearbhaill RE; Alektiar KM; Beal K; Gardner GJ; Long Roche KC; Sonoda Y; Chi DS; Zivanovic O; Leitao MM; Cadoo KA; Tew WP
Gynecol Oncol; 2019 Jul; 154(1):144-149. PubMed ID: 31113680
[TBL] [Abstract][Full Text] [Related]
23. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Škapa P; Dundr P
Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.
Mitamura T; Sekine M; Arai M; Shibata Y; Kato M; Yokoyama S; Yamashita H; Watari H; Yabe I; Nomura H; Enomoto T; Nakamura S;
Jpn J Clin Oncol; 2020 Dec; 50(12):1380-1385. PubMed ID: 32676635
[TBL] [Abstract][Full Text] [Related]
25. [Analysis of sequential chemotherapy efficacy in ovarian epithelial carcinoma, fallopian tube carcinoma and primary peritoneal carcinoma].
Shen XY; Li XP; Wang Y; Wu Y; Li Y; Yang YC; Wei LH; Fan Y; Tang ZQ
Zhonghua Fu Chan Ke Za Zhi; 2024 May; 59(5):383-390. PubMed ID: 38797568
[No Abstract] [Full Text] [Related]
26.
Kim DH; Cho CH; Kwon SY; Ryoo NH; Jeon DS; Lee W; Ha JS
J Gynecol Oncol; 2018 Nov; 29(6):e90. PubMed ID: 30207098
[TBL] [Abstract][Full Text] [Related]
27. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
Sioulas VD; Schiavone MB; Kadouri D; Zivanovic O; Roche KL; O'Cearbhaill R; Abu-Rustum NR; Levine DA; Sonoda Y; Gardner GJ; Leitao MM; Chi DS
Gynecol Oncol; 2017 Apr; 145(1):15-20. PubMed ID: 28238354
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
Azribi F; Abdou E; Dawoud E; Ashour M; Kamal A; Al Sayed M; Burney I
BMC Cancer; 2021 Dec; 21(1):1350. PubMed ID: 34930165
[TBL] [Abstract][Full Text] [Related]
29. Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.
Weiss AS; Swisher E; Pennington KP; Radke M; Khasnavis N; Garcia RL; Kilgore MR; Lee MK; Norquist BM
Gynecol Oncol; 2020 Oct; 159(1):214-220. PubMed ID: 32709535
[TBL] [Abstract][Full Text] [Related]
30. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Pennington KP; Walsh T; Harrell MI; Lee MK; Pennil CC; Rendi MH; Thornton A; Norquist BM; Casadei S; Nord AS; Agnew KJ; Pritchard CC; Scroggins S; Garcia RL; King MC; Swisher EM
Clin Cancer Res; 2014 Feb; 20(3):764-75. PubMed ID: 24240112
[TBL] [Abstract][Full Text] [Related]
31. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis.
Sun C; Li N; Ding D; Weng D; Meng L; Chen G; Ma D
PLoS One; 2014; 9(5):e95285. PubMed ID: 24788697
[TBL] [Abstract][Full Text] [Related]
32. BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
Gorodnova T; Sokolenko A; Ni V; Ivantsov A; Kotiv K; Petrik S; Amelina I; Berlev I; Imyanitov E
Int J Gynecol Cancer; 2019 May; 29(4):779-786. PubMed ID: 30839285
[TBL] [Abstract][Full Text] [Related]
33. Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study.
Kim SI; Lim H; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Lee M
Cancer Res Treat; 2023 Jan; 55(1):245-257. PubMed ID: 35879854
[TBL] [Abstract][Full Text] [Related]
34. BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
Tsibulak I; Wieser V; Degasper C; Shivalingaiah G; Wenzel S; Sprung S; Lax SF; Marth C; Fiegl H; Zeimet AG
Br J Cancer; 2018 Sep; 119(6):683-692. PubMed ID: 30111871
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of
Gupta S; Rajappa S; Advani S; Agarwal A; Aggarwal S; Goswami C; Palanki SD; Arya D; Patil S; Kodagali R
JCO Glob Oncol; 2021 Jun; 7():849-861. PubMed ID: 34101484
[TBL] [Abstract][Full Text] [Related]
36. Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
Manning-Geist BL; Chi DS; Long Roche K; Zivanovic O; Sonoda Y; Gardner GJ; O'Cearbhaill RE; Abu-Rustum NR; Leitao MM
Gynecol Oncol; 2021 Aug; 162(2):345-352. PubMed ID: 34045053
[TBL] [Abstract][Full Text] [Related]
37. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
39. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
Piek JM; Torrenga B; Hermsen B; Verheijen RH; Zweemer RP; Gille JJ; Kenemans P; van Diest PJ; Menko FH
Fam Cancer; 2003; 2(2):73-8. PubMed ID: 14574155
[TBL] [Abstract][Full Text] [Related]
40. Real-world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau.
Cao Y; Chen H; Huang Y; Hu H
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1180. PubMed ID: 32721133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
